Corona RemediesQ3 FY26

Corona Remedies Q3 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,275.6P/E: 63.3Market Cap: ₹13.9K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • CORONA Remedies aims for 15% compound annual growth rate (CAGR) in revenue over the next 3 to 4 years.
  • The target for profit after tax (PAT) or earnings per share (EPS) growth is around 20% year-on-year for the next 3 to 4 years.
  • Revenue growth is generally steady with minor seasonal variations; Q3 sees slightly less growth due to festive season.
  • The company plans to expand its sales force by 5-7% annually, supporting growth and new therapy launches.
  • Expansion into new therapies like infertility, spine, rheumatoid, CNS, dermatology, and gastrointestinal is expected to drive additional growth.
  • International business is in early stages but aims to contribute with hormonal products post plant commissioning, targeting higher single-digit contribution in a couple of years.

See what Corona Remedies management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The transcript does not mention any current or planned fundraising through equity.
  • There is no explicit discussion about raising debt in the call.
  • Focus appears to be on organic growth and limited acquisitions (small acquisition from Bayer-Zydus done recently around INR 7.5-8 crores).
  • Plans include expanding manufacturing capacity, launching new therapies, and increasing marketing force funded through internal accruals.
  • No direct indication of external fundraising through either debt or equity in the immediate or near future.

See what Corona Remedies management said on order book — free account, 30 seconds.

Capex plans

Yes
  • CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27.
  • The company aims to obtain WHO and EU GMP certifications for this plant by the end of FY '27 to ramp up its international hormonal products business.
  • There is a significant solar power investment: an existing 1.3 MW solar plant at Bhayla and a planned 4.25 MW solar park covering 11.9 acres, aimed at reducing electricity costs and supporting ESG initiatives.
  • CORONA is actively evaluating inorganic growth opportunities via M&A and in-licensing but remains selective, focusing on strategic fit and brand alignment rather than solely company origin.
  • The focus is on expanding marketing and field force by 5-7% annually to support growth and new therapy launches, indirectly requiring investment in human capital.

Track Corona Remedies — get its next earnings analysis in your feed

How does Corona Remedies rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisCorona Remedies
Rev 3Mar 3

How does Corona Remedies rank in Pharmaceuticals & Biotechnology?

Compare Corona Remedies against every Pharmaceuticals & Biotechnology company (Q3 FY26) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →